Osteonecrosis (ON) of the femoral head is a potentially disabling condition affecting primarily young active adults. We can alter the course of the disease by early recognition, diagnosis and targeted treatment. There are different systems of diagnosis and classification of femoral head ON and different courses of treatment have been developed for each stage with variable success. Any attempt to depict an osteonecrotic lesion should use magnetic resonance imaging with adequate fat suppression. Fast magnetic resonance sequence at multiple sites in patients with ON is an inexpensive, secure and fast way of early diagnosis. Our intention is to highlight certain aspects of hip osteonecrosis concerning etiology, differential diagnosis and management, such as steroid induced osteonecrosis and acute bone marrow edema syndromes.
Introduction
Osteonecrosis (ON) is the death of bone and its catastrophic results following disruption of bone vascular supply. Apart from idiopathic cases, causes are trauma, which is the commonest, and non-traumatic systemic conditions (commonest: alcoholism, corticosteroid therapy, hematologic disease, systemic erythematous lupus) (table I). There are two major types of ON: medullary bone infarction, involving the trabecular architecture and marrow cavities in metaphyseal sites which is in most cases clinically silent; and the juxta-articular infarction, which are located at the subchondral bone at major joints, which is usually symptomatic. The disease in the majority of the patients is affecting the hip joint and could be followed by the contralateral hip, the humeral head, the knee, the ankle and less commonly the elbow and small bones of the wrist [1] . In most patients, the natural history of femoral head ON (FHON) leads to collapse of the femoral head and destruction of the hip joint at an early age. Consensus has yet to be achieved among authors worldwide for specific guidelines of staging and treatment of symptomatic or asymptomatic FHON.
There are different systems of diagnosis and classification of femoral head ON and different courses of treatment have been developed for each stage. Any attempt to depict an osteonecrotic lesion should use magnetic resonance (MR) images with adequate fat suppression, since the contrast of the lesion against the low signal intensity of the bone marrow is high. Historically, investigators had difficulty evaluating the fate of asymptomatic ON because the disease could not be clearly detected in asymptomatic hips by simple radiographs. However, with the advent of MRI, it became easier to diagnose asymptomatic disease and to more accurately ascertain the extent, location, and stage of the necrotic lesion that determine prognosis of ON of the femoral head [2] . Our intention is to highlight certain aspects of hip osteonecrosis concerning etiology, diagnosis and treatment performing a brief review of literature.
REVIEW

Etiology -pathophysiology
We would like to focus on risk factors for developing FHON that can be calculated and/or prevented. The incidence of ON has increased in parallel with the rise in glucocorticoid therapy for treatment of systemic conditions as well as organ transplantation. It has been assumed that steroid-induced ON results from an increase in intraosseous pressure from excessive marrow fat accumulation or a shift in the differentiation of marrow stem cells into adipocytes. The next step in this chain of events is a reduction in the pool of stem cells available for osteoblast production, ultimately leading to insufficient repair and remodeling of necrotic bone. Daily and cumulative doses as well as route of administration and maximum dose, affect risk of development of osteonecrosis. Unidentified genetic factors could play a role. Patients on steroid therapy have a 20-fold relative danger to develop ON. Parenteral or oral steroids are more likely to lead to osteonecrosis. The highest daily dose, or, to a lesser extent, cumulative dose is directly correlated with the risk of developing osteonecrosis [3] . In a meta-analysis recently published, an osteonecrosis incidence of 6.7% (range 0.3 -52%) among high corticosteroid use patients (2g of prednisone was defined as high corticosteroid use) was reported. It was also of interest the different incidence of osteonecrosis in different diseases, such as severe acute respiratory syndrome (SARS) (21.8%), systemic lupus erythematosus (SLE) (15.7%), renal transplant (14.7%) and bone marrow transplant (6.6%). Irrespective of the underlying pathology, positive association between mean corticosteroid use and the occurrence of osteonecrosis was observed. Dose adjustments seem to affect the incidence of osteonecrosis, since a 10mg increase per day lead to a 3.6% increase in the rate of osteonecrosis. Osteonecrosis is rare in patients who are on very short, low dose course protocols [4] . Topical and inhaled steroids have been reported to be associated with osteonecrosis, but these cases were confounded by the use of oral or parenteral steroids as well. No cases of osteonecrosis were found that were associated with the use of topical or inhaled steroids alone. Unfortunately, only the minority of affected cases with ON are ever reported [5] .
In cases of trauma, the resulting osteonecrosis is expected and its pathophysiology is better understood as blood perfusion of the femoral head is critically compromised. In patients with a subcapital fracture for instance, vascularity of the femoral head depends only on the perfusion from the ligamentum teres which normally provides the blood supply to 10-20% of the femoral head. In patients with a hip dislocation, blood supply from the ligamentum teres is interrupted and perfusion of the femoral head depends on the severity of the injury of the retinacular vessels around the dislocated head and the pressure of the intracapsular hematoma. Surgery for pelvic or acetabular fractures can also be a cause for ONFH as the surgeon may need to control excessive bleeding by ligating or cauterizing nourishing vessels of the head [6] . Intravascular coagulation appears to be the most common pathogenetic mechanism through which various unrelated risk factors lead to ischemia and subsequent death of bone Early flattening of dome, crescent sign, CT may be needed, extent of involvement A, B or C, further characterization by amount of depression (in mm) 4 Flattening of the femoral head with joint space narrowing, possible other signs of osteoarthritis and marrow cells. Parsons and Steele suggested the possibility of screening tests for patients suffering from hypercoagubility disorders, since some of these disorders have a known inheritance pattern. Thrombophilia marks tendency for thrombosis and hypofibrinolysis is the reduced ability to dissolve thrombi. Both those thrombotic states can cause intravascular coagulation. To be more specific, hypofibrinolysis may be due to elevated levels of plasminogen activator inhibitor 1, and/or decreases in tissue plasminogen activator or he presence of lipoprotein associated antigen Lp(a). Another cause of hypofibrinolysis can also is resistance to activated protein C. Factor V Leiden results from arginine to glutamine substitution in the factor V peptide chain; as this occurs at the point of cleavage of factor V by its regulatory protein which is protein C it makes factor V resistant to inactivation. This is measured clinically as resistance to activated protein C. Altered anti-phospholipid antibody levels, such as lupus anticoagulant, and anticardiolipin antibodies, cause hypercoagulability. They react against a b-2 glycoprotein in endothelial cell membranes and promote the activation of soluble clotting factor [6, 7] . They based their view on the work of Jones et al [8] . However this was contradicted by Lee et al who inserted the idea of ethnic differences [9] . Jones and Hungerford also commented on the subject that it could also be due to differences in analytical techniques, experimental design, or data analysis [10] .
Symptomatology -imaging -classification
The pattern of pain in patients with ONFH is not unique; it can correspond to numerous pathologies involving the hip joint and is insidious. Initial pain (if any) is vague in nature, noticed with sit to stand, stair climbing, walking on inclination and impact loading. Pain location tends to be most specific in anterior hip and lower pelvis. Can be acute in onset (acute infarct phenomenon), which can mimic an acute injury. Range of motion is reduced and gait is affected. Confirmation of diagnosis is radiological. What is of critical importance for the orthopedic surgeon and the musculoskeletal radiologist is high degree of suspicion when history and presentation point toward FHON. The typical patient's profile is a relatively young (35-50) male (7:3 male to female ratio) with associating risk factors for FHON [1] .
The radiographic findings are important for every clinician to know, in order to be suspicious of an osteonecrotic lesion before it becomes symptomatic or too progressed, especially on a plain radiograph. A marked sclerotic rim surrounding an osteopenic lytic lesion is an early pathognomonic sign, depicting reactive bone remodeling at the necrotic viable osseous junction. This pattern characterizes stage II disease according to the modified Ficat-Arlet, Steinberg's and ARCO systems (Tables II, III , and IV). A crescent lucent subchondral line resulting from a subchondral fracture should always be recognised. The presence of the "crescent" sign in the absence of segmental flattening, classifies the lesion as stage III in all major staging systems. Finally, and as a sign of advanced ONFH segmental collapse of the femoral head with or without joint space narrowing and secondary osteoarthritis [6] .
Diagnosis of osteonecrosis has sensitivity and specificity of 91% and 99%, respectively if any two of the following criteria is present: collapse of the femoral head without joint-space narrowing or acetabular abnormality on x-ray images (including crescent sign); demarcating sclerosis in the femoral head without joint-space narrowing or acetabular abnormality; "cold in hot" on bone scans; low intensity band on T1-weighted images (bandlike pattern); and trabecular and marrow necrosis on histology [2] . MRI is however the method of choice for diagnosing but more importantly for staging ON. We highly recommend fast MR SE sequences available in high-field MR scanners. Typical of ONFH is the subchondral "band-like" sign with low signal intensity rim surrounding the necrotic lesion observed in coronal T1w and the "double-line" sign seen on axial T2w Turbo Spin Echo images. Applying a larger field of view and lower acquisition matrix values, the examination time might be significantly reduced, making it ideal for a fast examination when suspicion of multifocal ON is high. Therefore, at the presentation of a patient with hip ON and musculoskeletal pain other than that at the buttock, hip and thigh area, 2-3 additional anatomical sites can be screened with Fast MR imaging at the same time as the one subjected to a detailed MRI scan [11] . Fast MR imaging is an accurate and reliable diagnostic tool for following up patients with osteonecrosis and investigating skeletal pain in patients with known femoral head ON (figure 1). Fast MR imaging is particularly helpful for patients with hip ON of secondary etiology where a considerable possibility for multiple ON lesions exists. The fat suppressed T2-w TSE sequence can be applied as a reliable investigation exam and as the single most sensitive and specific diagnostic tool in patients with osteonecrosis.
Bone marrow oedema is the main, non-specific MR finding in a series of diseases, including FHON and could cause confusion to the treating physician. It is however present at different progression stages for each disease. Acute bone marrow edema syndromes (BMEs) (transient osteoporosis of the hip, regional migratory osteoporosis, chronic regional pain syndrome), must be differentiated from osteonecrosis because of the difference course of disease and treatment for each entity. The presence of bone marrow oedema when confined to a single location is not a specific finding. It can be caused by trauma, tumour, infection, osteonecrosis, transient osteoporosis, altered weight bearing, physiological stress responses or any arthropathy, inflammatory or degenerate. One should however realise that avascular necrosis is a disease of the femoral head, whereas the pattern of bone marrow oedema in BMEs could involve the femoral and proximal shaft of the femur [12] . A second important but not absolute criterion to help differentiate between FHON and BMEs is the presence or not of the risk factors for FHON and the patient profile. Finally, in order to clarify this as much as possible, the MR signs of femoral head osteonecrosis are never found in BMEs. The only common finding is bone marrow oedema. To be even more specific, apart from this, bone marrow edema is only present in ONFH in advanced disease, when disease has progressed to the stage of articular collapse. The appearance of necrosis is unique on MR imaging and should not be confused with the microtrabecular insufficiency subchondral fractures found in THO [6, 12] .
In their systematic review of the literature, Mont et al. identified 16 different classification systems. Of these, historically and practically, the most important, prominent and most frequently used ones are the Ficat classification (63% of published literature, table II), the University of Pennsylvania (Steinberg, table III) system (20%), the association research circulation osseous (ARCO, table IV) system (12%) and the Japanese Orthopedic Association system (5%). An ideal classification system would include radiographic and MR criteria for early diagnosis, patient symptomatology and interobeserver reproducibility [13] .
In a recent survey among members of Society of Skeletal radiology with surprising results, only half of the study sample (45 %) used a specific classification system. In accordance with the above, that was in the majority of answers the 1970 Ficat and Arlet classification. More comprehensive systems were rarely used. Much to the authors' satisfaction, 121 out of 121 respondents indicated that the extent of necrosis and joint involvement were of clinical importance, and that 115 felt that a musculoskeletal radiologist should attempt to determine this. This was supported by the fact that 113 of the 121 respondents did use some method to indicate the extent of necrosis. One hundred and seven used visual estimates, and there were 76 positive responses regarding the use of angular or 3D measurements on radiographs or MRI. A simple visual estimate by an experienced observer is both practical and clinically useful. However, neither the specific factors included in this visual estimate could be determined nor how the extent of involvement was expressed. It is important that such an estimate be clearly defined and be incorporated into a comprehensive classification system and not be presented as a separate parameter of evaluation [14] .
Treatment
Optimal treatment of asymptomatic osteonecrosis of the femoral head is not well defined. A small or medium-sized lesion causes stress to the responsible treating physician into watchful and sometimes wishful waiting, believing that only a minority of lesions will progress to symptomatic disease. In contrast, others are more daring with their approach believing that many patients who are asymptomatic will eventually progress to symptomatic disease, and advocate joint-preserving surgical treatment for these patients to forestall almost inevitable disease progression and the eventual need for a total hip arthroplasty. However, rather than adopting a single approach for all patients, it might be possible to identify various factors that portend a better or worse outcome in patients with asymptomatic disease. For example, the size of necrosis is important in predicting whether a fracture and further joint destruction will occur. Location of the necrotic lesion may affect the likelihood of disease progression, and other demographic and/or radiographic parameters might influence the prognosis of this disease [6, 15] .
In 2010, Mont et al studied data from previous published works aiming at evaluating progression of asymptomatic FHON to symptomatic disease and femoral head collapse. Of 664 hips that were considered eligible for inclusion for asymptomatic disease, 59% progressed to symptomatic disease and/or collapse over a mean follow-up period of 88 months (range in studies, 2 to 240 months). Risk factors played a major part in the course of the disease. For example, patients suffering from sickle disease had 73% chance of disease progression and femoral head collapse, whereas patients with systematic erythematous lupus only 17%. Based on their analysis, the authors concluded that large lesions have a risk of progression as high as 84%, whereas medium size lesions have a more moderate chance of progression (25%). However, small (<25% of the femoral head) and medially located lesions have a more benign course with a risk of progression of <10%, making them more appropriate for non-operative treatment [15] .
A different method of prediction of femoral head collapse and treatment option was investigated by Ha et al [16] . They introduced a modification in the combined Kerboul angle to predict disease progression to collapse. Their angle was the combination of necrotic angle in midsagittal and midcoronal MR images. Although their sample was relatively small (n=37 femoral heads in 33 patients), they reached a similar conclusion with Kerboul in a follow-up of ranging from time of head collapse or a minimum of 5 years. After initially dividing their patients into groups on the basis of magnitude of necrotic angle, they reached the conclusion that hips belong to 3 groups with escalated risk; those with a combined necrotic angle of ≤190° belong to a low-risk group, those with an angle between 190° and 240° are in the moderate-risk group, and those with an angle of ≥240° are in the high-risk group. Moreover, the authors suggested that this should be a new way to classify and predict progression to disease and they also presented fairly good results on reproducibility of their method. They recognize however that further investigation is required to verify their method.
Treatment can be broadly categorized into two types; treatment in the precollapsed or early collapsed stage (<2 mm of joint collapse) and treatment after advanced collapse or osteoarthritis of hip joint.
Bisphosphonate inhibits the osteoclastic activity in the osteonecrotic lesion site and thus promotes bone healing. In a recent publication of 53 hips (in 40 patients) at 10 year follow-up a 29% collapse rate was reported in the precollapse stage of ON (10 of 34 hips) following a course of continuous alendronate use at 70 mg weekly in the first 3 years or until clinical failure was obvious [17] . The investigators thus concluded that the natural history of untreated ON with more than 70% collapse rate was favorably altered with alendronate use. We would like to point out that according to a recent review, the collapse rate of untreated FHON is 59% [15] . In two very recent review studies, beneficial effects of alendronate use with or without physical therapy have been suggested for practically any stage of ONFH [18, 19] . However, the treating physician should bear in mind that bisphosphonate therapy could only delay and not utterly prevent the need for surgical intervention. A catastrophic but rare complication of jaw osteonecrosis has been reported, although the American Association of Oral and Maxillofacial Surgeons has allowed the use of this drug for 3 years without increment in the risk of jaw osteonecrosis [20] . Guidelines for stage, dose, duration and complications of treatment have yet to be clearly established.
Lipid lowering agents are considered to be helpful in ONFH particularly in steroid-induced ON. Statins inhibit HMG-CoA reductase, the enzyme that normally catalyses the last step in cholesterol synthesis. These drugs reduce serum Low Density Lipoprotein (LDL) activity and reduce the entry of LDL into the circulation. Two mechanisms are thought to lead to steroid induced osteonecrosis: the accumulation of fat in the rigid marrow cavity causing an intra-osseous compartment syndrome and the differentiation of osteoprogenitor cells along an adipocyte lineage, so reducing the number of cells available for repair and remodeling of necrotic bone. Affecting either of these steps could be expected to reduce the risk of osteonecrosis. It was reported that after mean follow-up of 7.5 years, only 1% of patients taking high-doses of corticosteroids and statin drugs developed ONFH, whereas the prevalence was 3-20% in patients receiving high-dose corticosteroids without statins [21] . But Ajmal et al did not find any significant reduction in ON between patients taking steroid and statin versus steroid without statin (4.4% vs. 7%) [22] . Literature is rare and mainly of animal-based studies and large randomized studies are needed to establish its efficacy in ONFH.
Extra-corporeal shock wave therapy (ESWT) has been found in a study with long term follow-up (up to 9 years) to be more effective than core decompression and fibular grafting, leading to regression of some small lesions and succeeding pain relief [23] . The mechanism is felt to be secondary to micro-fracture caused by the shock waves. In a previous study from the same author, histopathological analysis on femoral heads previously treated with ESWT was performed and it was suggested that the mechanism responsible for regeneration is promotion of angiogenesis and bone remodeling [24] . Vulpiani et al evaluated the outcome of ESWT in early-stages ONFH (ARCO I to III). They concluded that ESWT in ARCO Stages I and II slows down the worsening of the grade of the ONFH and improve clinical features [25] . Short follow-up, small sample studies and technique are the major limitations for its restricted use.
Operative treatment of ONFH consists of core decompression, non-vascularized bone grafting, vascularized bone grafting, and administration of bone morphogenetic proteins, stem cell therapy, proximal femoral osteotomies, and hip arthroplasty.
Lieberman et al concluded after an extensive literature research and meta-analysis that no one procedure had better results delaying total hip arthroplasty (THA) or radiographic progress of the disease, and 15 such operative procedures were identified. The authors also found that as far as small lesions are concerned (<15% of the femoral head and <200 0 total necrotic angle) in the pre-collapse stage, core decompression, which is the commonest procedure performed, with or without bone grafting, has an acceptable failure rate (14-25%) and is therefore recommended. In the post-collapse stage, the data showed that salvation of the femoral head could not be achieved [26] .
Research is very much still ongoing for the development of non-invasive techniques to cure FHON or at least delay its currently inevitable course towards THA in a relatively young age. Adult tissue derived mesenchymal stem cells application is a promising prospect. Stem cells have been shown to promote bone formation and favor neovascularization in vitro. Several clinical studies have also been conducted including stem cell therapy and traditional surgical methods such as core decompression, reporting positive results. However, considerable variations and inconsistent reporting among clinical studies regarding the dose of stem cells (dose and quality have been reported to affect disease outcome) and indication for their use (lesion size, and severity/classification of disease) has made comparisons between studies challenging [27] .
All of the aforementioned modalities aim at delaying the necessity of THA at a very early age that would in turn lead to possibly multiple revisions in a lifetime. THA is currently the only solution to restore both function and relieve the patient's symptoms. The latest results with long-term follow-ups show no difference in survivorship of implants among control and FHON patients, even with previous surgical interventions. Cup wear or loosening was found to be more common than stem loosening [28] [29] [30] [31] .
Conclusion
Literature on ON is quite extensive and highly specific, meaning that it is not always easy for the inexperienced clinician to identify all aspects of this entity. Our goal is to concentrate and highlight useful conclusions from research work that could be applied to everyday practice. We consider steroid-induced osteonecrosis a form of iatrogenic disease and all physicians should have a high level of suspicion for its detection. BMEs should not cause any further confusion and fast MR sequence at multiple sites in patients with ON is an inexpensive, secure and fast way of early diagnosis.
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